Key Takeaways
- Agrochemical weakness drove a steep Q2 drop: Revenue fell to ₹270 crores from ₹310 crores QoQ as an extended monsoon disrupted spray cycles, delayed harvests and built channel inventory.
- H1 still grew, but profitability compressed: H1 revenue rose 9% YoY to ₹580 crores, yet EBITDA fell to ₹72 crores (from ₹88 crores) and PAT dropped 20%, reflecting the operating deleverage of the weak Q2.
- The diversification pivot is now producing signed deals: A binding term sheet for a five-year, ₹35-40 crore annual contract manufacturing deal in specialty chemicals, plus a commissioned biocide expansion and commenced long-term supplies, mark tangible progress away from agrochemicals.
- Full-year margin guide held, but the path is back-end loaded: Management reiterated 13% to 15% EBITDA margins for FY26 despite H1 at ~12% and a seasonally lean Q3 ahead, pinning recovery on Q4 normalization.
- What to watch next quarter: Whether the new R&D center goes live on schedule, any early signs of agrochemical inventory clearance ahead of the hoped-for Q4 revival, and progress on the ₹40 crore CAPEX for the new contract manufacturing line.
Agrochemical Demand Disruption
- Extended monsoon broke the season: Rainfall persisted as late as November in parts of India, delaying sowing and harvesting, disrupting spray cycles, causing significant crop damage, and leaving elevated channel inventory.
- Inventory overhang quantified: Inventory levels rose 15% to 20% from Q1, directly tied to the agrochemical channel buildup.
- Recovery thesis rests on groundwater and winter crop: Abundant groundwater levels create the possibility of a better winter crop cycle, but full-scale revival is not expected before Q4 or later, depending entirely on the pace of inventory clearance.
- Q3 will stay lean: Q3 is historically a lean quarter for agrochemicals, and the extended monsoon compounds that seasonality.
Ravi Shroff: "We see normalization of demand to some extent due to abundant groundwater levels resulting in a better winter crop cycle. This is our expectation if there are no other disruptions and full-scale revival of demand could happen sometime in Q4 or little beyond that."
Diversification: Contract Manufacturing & Performance Solutions
- Binding term sheet signed: A five-year contract manufacturing and supply arrangement with a reputed Indian specialty chemicals company, for a product outside the agrochemical space. The customer supplies raw materials and has provided a ₹25 crores trade advance.
- New dedicated line, meaningful revenue: Excel will invest ₹40 crores to build a dedicated production line, commissioning by June 2026, targeting annual revenue of ₹35-40 crores excluding raw material cost. The deal is expected to be EBITDA accretive.
- Revenue ramp will be staggered: The contract covers three different products or projects, so revenue will phase in over 12 to 18 months with no precise peak timing yet.
- Three recent wins, all in performance solutions: All three contract manufacturing opportunities secured in the last 12 months sit in the performance solution segment, consistent with the stated goal of reducing agrochemical dependence.
- Evaluation criteria are explicit: Excel screens for fit with existing capabilities and assets, available environmental approvals, EBITDA-accretive margin profile, acceptable IRR, and the strategic factor of lowering agrochemical concentration.
- Long-term supply deal now shipping: Initial supplies under the long-term arrangement with a leading multinational (disclosed May 2025) have commenced.
- Biocide capacity online: The capacity expansion of a key biocide product was commissioned in October 2025, with full-year revenue expected at ₹15 crores.
- Polymer contract adds another layer: A separate polymer contract is expected to deliver ₹10-12 crores in topline at full stream.
Ravi Shroff: "This arrangement will leverage the customer's market access for the downstream end products and our strengths in core areas to deliver a win-win for both organizations. For our company, this is a significant step towards strengthening our position in contract manufacturing and will reduce our dependence on the agrochemical sector."
Margins: Compressed Today, Guided to Recover
- H1 margin undershoots the full-year guide: H1 operating margin came in at approximately 12%, below the 13% to 15% full-year target, driven by the operating deleverage of the Q2 revenue decline.
- Guide reaffirmed, but conditionally: Management maintained the 13% to 15% EBITDA margin range for FY26 and on an ongoing basis, while acknowledging the H1 miss and a seasonally lean Q3. When pressed, the response was non-committal: "there is a possibility."
- Recovery math is back-end loaded: Achieving the guided range requires a meaningful Q4 normalization in agrochemical demand and volume, plus contribution from new performance-solution streams.
- Raw material prices moving up: Raw material costs rose in the recent quarter, though Excel has limited sourcing exposure to China. Management declined to give an H2 price outlook, calling it too dynamic.
CAPEX & Capacity
- Three-year CAPEX envelope: ₹200-300 crores planned over the next three years, covering both maintenance and growth initiatives.
- Near-term growth CAPEX identified: The ₹40 crores dedicated line for the new contract manufacturing deal is the largest discrete project, with commissioning targeted by June 2026.
- Capacity utilization has headroom: Current utilization runs at 70% to 75%, with 85% to 90% considered maximum effective utilization given product-line mix, operational flexibility needs, and periodic maintenance.
- Management declined to quantify peak revenue potential from existing capacities at current pricing, calling topline projections too difficult.
R&D Build-Out
- New R&D center on track for Q3: Launched last year, the facility is expected to become operational during Q3 FY26. Infrastructure and people requirements have been evaluated.
- R&D positioned as a core growth pillar: Excel is actively exploring additional strengths needed, with the ambition to make R&D central to long-term portfolio expansion.
- New product selection criteria defined: The company prefers multi-step synthesis where it can backward integrate, combined with a technology asset or other fit that meets financial parameters on IRR and contribution profile.
Ravi Shroff: "We are actively exploring what other strengths are required. And along with the new R&D center whatever we require in terms of other infrastructure, people as well, we have evaluated all of that to make sure that R&D becomes a core pillar of growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 13% to 15% for full year FY26 and on an ongoing basis | FY26 |
| Demand normalization | Full-scale agrochemical demand revival, conditional on inventory clearance pace and no further disruptions | Q4 FY26 or beyond |
| New contract manufacturing line | Dedicated production line commissioned; ₹40 crores investment; ₹35-40 crores annual revenue ex-raw material | Commission by June 2026; revenue staggered over 12-18 months thereafter |
| Biocide plant revenue | ₹15 crores full-year revenue from newly commissioned capacity | FY26 |
| Polymer contract revenue | ₹10-12 crores topline at full stream | At full stream (timing unspecified) |
| CAPEX | ₹200-300 crores total, including maintenance and growth | Over next three years |
| New R&D center | Facility to become operational | Q3 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | ₹270 cr, down from ₹310 cr in Q1 FY26 |
| Exports share | 17.7% of total revenue |
| EBITDA | ₹30 cr, down 29% sequentially from ₹42 cr |
| Profit after tax | ₹19 cr, down from ₹34 cr in Q1 FY26 |
| H1 FY26 revenue | ₹580 cr, up 9% YoY from ₹534 cr |
| H1 FY26 EBITDA | ₹72 cr, down from ₹88 cr in H1 FY25 |
| H1 FY26 profit after tax | ₹52 cr, down 20% YoY |
| Full-year EBITDA margin guidance | 13% to 15%, maintained |
| Capacity utilization | 70% to 75% across the company |
| Inventory increase | 15% to 20% from Q1 FY26, agrochemical segment |
| New contract manufacturing investment | ₹40 cr, dedicated production line, commissioning by June 2026 |
| New contract manufacturing expected annual revenue | ₹35 cr to ₹40 cr, excluding raw material cost, EBITDA accretive |
| New biocide plant investment | ₹10.33 cr, commissioned October 2025 |
| New biocide plant expected full-year revenue | ₹15 cr, EBITDA accretive |
| Three-year CAPEX plan | ₹200 cr to ₹300 cr, including maintenance and growth CAPEX |